10-Q: DIH Holding US, Inc. Reports Increased Revenue and Reduced Net Loss in Q2 2025

DIH Holding US, Inc. saw a significant increase in revenue and a substantial reduction in net loss for the quarter ended September 30, 2024, compared to the same period last year.

Summary

• DIH Holding US, Inc. reported a revenue of $18.2 million for the three months ended September 30, 2024, a 39.1% increase compared to $13.1 million in the same period of 2023.
• The company's net loss for the quarter was $0.2 million, a significant improvement from the $2.5 million loss in the same quarter of the previous year.
• For the six months ended September 30, 2024, revenue reached $35.1 million, a 34.5% increase from $26.1 million in the same period of 2023.
• The net loss for the first six months of fiscal year 2025 was $0.5 million, a substantial improvement from the $5.4 million loss in the same period of the previous year.
• The company's gross profit margin improved due to a 10% price increase implemented in fiscal year 2024.
• Operating expenses increased due to costs associated with becoming a public company and increased personnel costs.
• The company issued $3.3 million in convertible debt in June 2024, with a maturity date of December 7, 2025.
• The company has three notes payable to a related party, each due on June 30, 2026, with an interest rate of 1.25%.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and net loss reduction, but the company still faces challenges related to profitability, internal controls, and going concern issues. The sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in revenue, driven by higher sales volume in EMEA and the Americas.
• The company substantially reduced its net loss compared to the previous year.
• Gross profit margins improved due to a price increase.
• The company secured $2.8 million in net proceeds from convertible debt financing.
• The company is taking steps to streamline its organization and cost structure to improve future revenue growth.

Negatives

• The company has a substantial accumulated deficit of $35.8 million.
• The company has negative cash flows from operating activities for the six months ended September 30, 2024.
• The company has negative working capital as of September 30, 2024.
• The company's operating expenses increased due to costs associated with becoming a public company.
• The company has a material weakness in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is in doubt due to operating losses and negative working capital.
• The company is exposed to risks related to supply chain disruptions and inflation.
• The company is subject to foreign currency fluctuations that can impact its reported revenues.
• The company faces challenges related to the implementation of EU MDR and other regulatory changes.
• The company's operations are exposed to various global macroeconomic factors, including the impact of conflict in Ukraine, supply chain disruption, higher interest rates and inflationary pressures.
• The company has a material weakness in its internal controls over financial reporting.

Future Outlook

The company expects revenue to increase sequentially in future periods as it anticipates demand for its products to expand in represented markets. The company continues to explore financing alternatives in debt or equity to fund its ongoing operations and to fulfill current obligations.

Management Comments

• The company is taking steps to streamline its organization and cost structure as well as improve future revenue growth.
• The company is implementing measures designed to improve its internal controls over financial reporting to remediate a material weakness.

Industry Context

The company operates in the medical rehabilitation device industry, which is experiencing growth due to an aging population and increasing demand for rehabilitation services. The company's focus on advanced robotic devices and technology positions it to capitalize on these trends.

Comparison to Industry Standards

• The company's revenue growth of 34.5% for the six months ended September 30, 2024, is strong compared to the industry average, which is estimated to be in the high single digits.
• The company's net loss reduction is a positive sign, but it still needs to achieve profitability to be competitive with established players in the industry.
• The company's gross profit margin improvement is a positive trend, but it needs to maintain this level of profitability to be sustainable.
• The company's reliance on related party transactions and the need for additional financing are potential risks that need to be addressed to be competitive with larger, more established companies in the industry.
• The company's implementation of a new financial system (Oracle) and compliance with EU MDR are common challenges faced by companies in the medical device industry.

Related Party Transactions

• The company has three notes payable to Hocoma AG, a related party.
• The company has a distribution agreement with Motek Group, a related party.
• The company has balances due to and from DIH Hong Kong, a related party.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and any potential capital raises.
• Employees will be impacted by the company's efforts to streamline its organization and cost structure.
• Customers will be impacted by the company's ability to deliver products and services.
• Suppliers will be impacted by the company's supply chain and purchasing decisions.
• Creditors will be impacted by the company's ability to meet its debt obligations.

Next Steps

• The company will continue to explore financing alternatives in debt or equity.
• The company will continue to take steps to streamline its organization and cost structure.
• The company will implement measures to improve its internal controls over financial reporting.
• The company will continue to monitor and address supply chain and inflationary pressures.

Key Dates

Keywords

rehabilitation devices, medical technology, robotic devices, physical rehabilitation, revenue growth, convertible debt, financial results, net loss, gross profit, operating expenses, supply chain, EU MDR, internal controls